Pre-made Lorigerlimab benchmark antibody ( Whole mAb, anti-PDCD1/PD-1;CTLA4/CTLA-4 therapeutic antibody, Anti-CD279,PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Lorigerlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1;CTLA4/CTLA-4 Antibody: Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Lorigerlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1;CTLA4/CTLA-4 Antibody: Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody |
|---|---|
| INN Name | Lorigerlimab |
| Target | PDCD1,CTLA4 |
| Format | Bispecific Mixed scFv (scFv-CH2-CH3-scFv) |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | G4;G4 |
| VD LC | Kappa,Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;5xj3:AB/5tru:HL/6jc2:HL/6rp8:hl/7erx:HL |
| Year Proposed | 2021 |
| Year Recommended | NA |
| Companies | MacroGenics |
| Conditions Approved | NA |
| Conditions Active | Solid tumours |
| Conditions Discontinued | NA |
| Development Tech | Dual-Affinity?Re-targenting (DART?) |
| Previous Name | NA |
| Gm Offical Target Name | PDCD1,CTLA4 |
| Package |
